Sugi Predict

Sugi Predict / Compounds / SCHEMBL17480291

SCHEMBL17480291

SCHEMBL17480291

Cc1cc(C)c(/C=C2\C(=O)Nc3ccc(-c4ncccc4C)cc32)[nH]1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 10/20 0.71
▸ ALK Q9UM73 6/20 0.71
▸ FLT3 P36888 4/20 0.71
▸ ABL1 P00519 2/20 0.71
▸ PDGFRB P09619 3/20 0.63
▸ KDR P35968 4/20 0.61
▸ CSF1R P07333 2/20 0.61
▸ FGFR1 P11362 2/20 0.61
▸ SRC P12931 2/20 0.61
▸ FLT1 P17948 2/20 0.61
▸ FGFR3 P22607 2/20 0.61
▸ MAPK1 P28482 2/20 0.61
▸ FLT4 P35916 2/20 0.61
▸ PDPK1 O15530 2/20 0.61
▸ NTRK1 P04629 2/20 0.61
▸ MEN1 O00255 1/20 0.61
▸ NPC1 O15118 1/20 0.61
▸ GMNN O75496 1/20 0.61
▸ USP2 O75604 1/20 0.61
▸ LMNA P02545 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17480301 0.89 RET (0.65) RETALKFLT3ABL1PDGFRB
SCHEMBL17480315 0.88 RET (0.72) RETALKFLT3ABL1PDGFRB
SCHEMBL17480305 0.85 RET (0.68) RETALKFLT3ABL1PDGFRB
SCHEMBL17480299 0.85 RET (0.62) RETALKFLT3ABL1PDGFRB
SCHEMBL5469456 0.83 RET (1.00) RETALKFLT3ABL1PDGFRB
SCHEMBL5469460 0.83 RET (1.00) RETALKFLT3ABL1PDGFRB
SCHEMBL17480333 0.83 RET (0.65) RETALKFLT3ABL1PDGFRB
SCHEMBL17480293 0.83 RET (0.77) RETALKFLT3ABL1PDGFRB
SCHEMBL17480314 0.82 RET (0.77) RETALKFLT3ABL1PDGFRB
SCHEMBL5988023 0.82 RET (0.64) RETALKFLT3ABL1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190241569-A1 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER BOSTON BIOMEDICAL INC (US) 2019-08-08 — — US disclosed
US-20160031888-A1 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER BOSTON BIOMEDICAL, INC. (US) 2016-02-04 — — US disclosed
US-20160031888-A1 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER BOSTON BIOMEDICAL, INC. (US) 2016-02-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241569-A1 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER MAP3K2, MAP3K1, MAP3K3 RET 348/4885ALK 1316/4885FLT3 192/4885
US-20160031888-A1 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER MAP3K19, MAP3K2, MAP3K3 RET 107/4885ALK 755/4885FLT3 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.